The National Institute for Innovation in Manufacturing Biopharmaceuticals
NIIMBL is a public-private partnership with the goal of advancing innovation in biopharmaceutical manufacturing. NIIMBL is part of Manufacturing USA, a network of 14 manufacturing institutes across the country that brings together industry, academia, and the public sector to propel promising research developments, accelerate new products to market, and train tomorrow’s workforce in order to secure America’s future. NIIMBL is funded through a cooperative agreement with the National Institute of Standards and Technology (NIST) in the U.S. Department of Commerce, and leverages additional support from industry, academic institutions, non-profit organizations, and the states of Delaware, Maryland, North Carolina, and the Commonwealth of Massachusetts.
The NIIMBL mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry.
Current MIT projects:
Continuous Cell Culture for Viral Vaccines
Participants: Massachusetts Life Sciences Center, Merck & Co., Inc., Repligen Corporation, University of Massachusetts Medical School
Small-scale Membrane-less Perfusion Bioreactor System for High-throughput Cell Line Development and Process Optimization
Participants: Massachusetts Life Sciences Center, Genentech, a member of the Roche Group, Merck & Co., Inc., MilliporeSigma, Whirlcell Pte. Ltd.
Nanofluidic Analytics Platform for Multi-Modal Bioprocess Monitoring and Real-Time Product Release
Participants: Genentech, a member of the Roche Group, MilliporeSigma, Massachusetts Life Sciences Center, Redbud Labs, Inc.